Leptin and breast cancer: An overview

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1510-1514

  Artac, Mehmet ^a   Altundag, Kadri ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Leptin; Prognosis; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TAMOXIFEN;

ANGIOGENESIS; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WEIGHT; BREAST CANCER; BREAST CARCINOMA; CELL PROLIFERATION; ENDOTHELIUM CELL; FOOD INTAKE; GENE OVEREXPRESSION; HUMAN; MITOGENESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WAIST HIP RATIO; WEIGHT;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; LEPTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84872773636     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0056-0     Document Type: Review

References (59)

1. Schapira DV, Kumar NB, Lyman GH, Cox CE. Obesity and body fat distribution and breast cancer prognosis. Cancer. 1991;67: 523-8.
2. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ. 2007;335:1134.
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-32.
4. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system 1-3. Am J Clin Nutr. 1999;69:584-96.
5. Goodwin PJ, Ennis M, Fantus IG, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037-42.
6. Garaulet M, Pérex-Llamas F, Fuente T, et al. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143:657-66.
7. Surmacz E. Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res. 2007;9:301.
8. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10:4325-31.
9. Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007;30:1499-509.
10. Bozcuk H, Uslu G, Samur M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27:58-65.
11. Hollmann M, Runnebaum B, Gerhard I. Impact of waist-hip-ratio and body-mass-index on hormonal and metabolic parameters in young, obese women. Int J Obes Relat Metab Disord. 1997;21: 476-83.
12. Borugian MJ, Sheps SB, Kim-Sing C, et al. Waist to hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158:963-8.
13. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-5.
14. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-81.
15. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 2005;83: 1263-71.
16. Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668-76.
17. Geisler C, Haynes B, Ekse D, et al. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Streoid Biochem Mol Biol. 2007;104: 27-34.
18. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 2002;21:1285-92.
19. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med. 1995;1:953-6.
20. Cirillo D, Rachiglio AM, Montagna R, et al. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105:956-64.
21. O'Brien SN, Welter BH, Price TM. Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun. 1999;259:695-8.
22. White DW, Tartaglia LA. Evidence for ligand-independent homo-oligomerization of leptin receptor (OB-R) isoforms: a proposed mechanism permitting productive long-form signaling in the presence of excess short-form expression. J Cell Biochem. 1999;73:278-88.
23. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272:32686-95.
24. Hynes GR, Jones PJ. Leptin and its role in lipid metabolism. Curr Opin Lipidol. 2001;12:321-7.
25. Fong TM, Huang RR, Tota MR, et al. Localization of leptin binding domain in the leptin receptor. Mol Pharmacol. 1998;53:234-40.
26. Hileman SM, Tornoe J, Flier JS, Bjorbaek C. Transcellular transport of leptin by the short leptin receptor isoform ObRa in madindarby canine kidney cells. Endocrinology. 2000;141:1955-66.
27. Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem. 2011;276:6343-9.
28. Devos R, Guisez Y, Van der Heyden J, et al. Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding. J Biol Chem. 1997;272:18304-10.
29. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004;64:5870-5.
30. Bjorbaek C, Elmquist JK, Frantz JD, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell. 1998;1:619-25.
31. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:30059-65.
32. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci USA. 2000;97:2355-60.
33. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683-6.
34. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2011;33:95-102.
35. Garonna E, Botham KM, Birdsey GM, et al. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with proangiogenic actions of leptin on human endothelial cells. PLoS ONE. 2011;6:e18823.
36. Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281:26320-8.
37. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 2011;104:128-37.
38. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008;67:128-45.
39. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and antropometric measures. Am J Clin Nutr. 2001;74:295-301.
40. Jarde T, Caldefie-Chezet F, Damez M, et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep. 2008;19:905-11.
41. Revillion F, Charlier M, Lhotellier V, et al. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 2006;12:2088-94.
42. Ozet A, Arpaci{dotless} F, Yilmaz MI, et al. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol. 2001;31:424-7.
43. Catalano S, Mauro L, Marsico S, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor a in MCF-7 cells. J Biol Chem. 2004;279:19908-15.
44. O'Neil JS, Burow ME, Green AE, et al. Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors a and b. Mol Cell Endocrinol. 2001;176:67-75.
45. Garafalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182, 780 in MCF-7 breast cancer cells. Clin Cancer Res. 2004;10:6466-75.
46. Kim Y, Kim SY, Lee JJ, et al. Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat. 2006;38:126-32.
47. Artac M, Bozcuk H, Ki{dotless}yi{dotless}ci{dotless} A, Eren OO, Boruban MC, Ozdogan M. Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs). ASCO Annual Meetings Proceedings, 2010, Abstract. 1106, Chicago, USA.
48. Nunez NP, Jelovac D, Macedo L, et al. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clin Cancer Res. 2004;10:5375-80.
49. Geisler J, Ekse D, Lonning PE (2006) The aromatase inactivator exemestane decreases plasma leptin levels in postmenopausal breast cancer patients. AACR, 97th Annual Meeting, 2006, Abstract 420, Washington DC, USA.
50. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125-38.
51. Eisenberg A, Biener E, Charlier M, et al. Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett. 2004;565:139-42.
52. Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study, preliminary in vivo analysis. BMC Cancer. 2008;8:305.
53. Soma D, Kitayama J, Yamashita H, et al. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res. 2007;149:9-14.
54. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
55. Otvos L Jr, Kovalszky I, Riolfi M, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47:1578-84.
56. Vona-Davis L, Rose DP, Howard-McNatt M, et al. Triple-negative breast cancer and obesity in a rural appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319-24.
57. Maiti B, Kundranda MN. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010;121:479-83.
58. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, breast cancer recurrence: a chort study. Breast Cancer Res. 2011;13:R34.
59. Nyante SJ, Gammon MD, Kaufman JS, et al. Common genetic variation in adiponectin, leptin and leptin receptor and associations with breast cancer subtypes. Breast Cancer Res Treat 2011 Apr 23. [Epub ahead of print].